Fortress Biotech, Inc. Common Stock (FBIO) Stock
NASDAQ · FBIO
Key stats
- Market cap
- $67.04M
- Price / Earnings ratio
- 0.6x
- EPS (TTM)
- $3.26
- Volume
- Loading
- 52-week high
- $4.53
- 52-week low
- $1.79
Source: third-party data provider, as of November 13, 2026
Compare with FBIO
Recent news

MarketBeat
Fortress Biotech Q2 Earnings Call Highlights
FBIOAugust 12, 2026
MarketBeat
Fortress Biotech Q2 Earnings Call Highlights
FBIO

Stocktwits
FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy
FBIOFebruary 23, 2026
Stocktwits
FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy
FBIO

Stocktwits
FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease
FBIOJanuary 13, 2026
Stocktwits
FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease
FBIO
Technical indicators
- RSI 14
- 50.19
- MACD 12/26/9
- -0.06
- EMA 9 of MACD
- -0.08
- MACD histogram
- 0.02
- SMA 50
- $2.17
- Price below SMA 50
- EMA 50
- $2.16
- Price below EMA 50
- SMA 200
- $2.73
- Price below SMA 200
- EMA 200
- $2.66
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
101M67M33M0
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
476M314M157M0
Revenue to Profit
2025$63.3M
Revenue$0.0
Cost of revenue$42.3M
Gross profit$0.0
Operating expenses$6.8M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

MarketBeat
Fortress Biotech Q2 Earnings Call Highlights
FBIOAugust 12, 2026
MarketBeat
Fortress Biotech Q2 Earnings Call Highlights
FBIO

Stocktwits
FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy
FBIOFebruary 23, 2026
Stocktwits
FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy
FBIO

Stocktwits
FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease
FBIOJanuary 13, 2026
Stocktwits
FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease
FBIO
About Fortress Biotech, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees78
CEODr. Lindsay Allan Rosenwald M.D.
IPO DateNov 17, 2011
HeadquartersBay Harbor Islands, FL
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Lindsay Allan Rosenwald M.D. | Executive Chairman, President & CEO | 1955 |
| Mr. David Jin | CFO & Head of Corporate Development | 1990 |
| Dr. Xiaoqin Lu M.D. | Chief Strategy Officer | 1975 |
| Mr. Michael S. Weiss Esq., J.D. | Executive Vice Chairman of Strategic Development & Director | 1966 |
Fundamentals
Valuation
Price-to-sales ratio1.10
Price-to-book value0.39
PEG ratio-0.10
Profitability
Return on Equity96.00%
Return on Assets40.00%
Return on Sales184.00%
Gross margin (latest quarter)67.18%
EBITDA$132.62M
Trading
Average volume211,490
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 50.19
- MACD 12/26/9
- -0.06
- EMA 9 of MACD
- -0.08
- MACD histogram
- 0.02
- SMA 50
- $2.17
- Price below SMA 50
- EMA 50
- $2.16
- Price below EMA 50
- SMA 200
- $2.73
- Price below SMA 200
- EMA 200
- $2.66
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -15.2 | -6.0 | ||||||||||
| 2022 | -24.0 | -24.4 | -18.1 | -21.4 | -15.6 | +5.3 | +7.6 | +18.1 | -17.3 | -2.7 | -25.1 | -0.9 |
| 2023 | +40.0 | -14.6 | +9.3 | -5.3 | -31.3 | +0.9 | +0.5 | -38.2 | -27.3 | -61.9 | +17.9 | +38.7 |
| 2024 | -24.2 | +5.6 | -17.7 | -16.1 | +5.7 | -9.5 | +23.7 | -2.9 | -26.4 | +32.9 | +12.1 | -11.7 |
| 2025 | -14.2 | -14.2 | +2.6 | +14.9 | +8.0 | +1.1 | +1.6 | +42.5 | +24.2 | +0.0 | +15.6 | +34.6 |
| 2026 | -23.1 | +8.6 | -15.5 | -6.9 | +20.2 | +19.1 | +1.3 | -0.7 | -20.1 | -7.2 | +4.1 |
Compare stocks
Market cap
$67.04M
-
-
-
Price / Earnings ratio
0.60
-
-
-
Price / Sales ratio
1.10
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
211,490
-
-
-
Earnings per share
$3.26
-
-
-



